<h4>Objective</h4>To identify prognostic factors and develop nomograms predicting short-term mortality and relapse in pediatric <i>RUNX1::RUNX1T1</i>-positive AML, thereby enabling individualized risk assessment and optimizing clinical management.<h4>Methods</h4>We retrospectively analyzed 136 pediatric patients with <i>RUNX1::RUNX1T1</i>-positive AML who achieved morphologic complete remission (CR) after one induction course under AML-CAMS-2009 or AML-CAMS-2016 regimen. The gene discussed is RUNX1; the disease is acute myeloid leukemia.